GlassScriptPhysician profile
Khaled A Sherif
NPI 1164736955
$12,672.20
in general payments reported to CMS, 2019-2025
21 companies · $5,536 in 2025
The $5,536 reported for 2025 was more than what 84% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $429 · 2023: $2,207 · 2024: $4,243 · 2025: $5,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,668 · Food and Beverage: $4,858 · Grant: $294 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,668.26 |
| Food and Beverage | $4,858.08 |
| Grant | $294.12 |
| Education | $165.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,674.09 | 2023-2025 | Turbohawk, Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $2,327.30 | 2023-2025 | Perclose Proglide, Esprit, Diamondback Coronary |
| Penumbra, INC. | $1,987.10 | 2023-2024 | Indigo System, Penumbra System |
| Edwards Lifesciences Corporation | $1,396.15 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $1,097.10 | 2019-2025 | Comet, Synergy, Watchman Flx |
| W. L. Gore & Associates, INC. | $788.68 | 2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Janssen Pharmaceuticals, INC | $192.29 | 2019-2024 | Xarelto |
| Shockwave Medical, INC | $188.96 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cook Incorporated | $140.85 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.84 | 2019-2020 | |
| Cardiva Medical, INC. | $114.03 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Cordis US Corp. | $102.06 | 2023 | Mynx Control |
| Nuwellis, INC. | $100.97 | 2019 | |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Amgen INC. | $76.24 | 2024-2025 | Repatha, Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Cook Medical LLC | $57.69 | 2024 | Advance |
| Biotronik INC. | $45.51 | 2020 | |
| Abiomed | $41.20 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $33.99 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $19.03 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Sherif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.